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Abstract Endochondral bone formation requires a cartilage
template, known as the growth plate, and vascular invasion,
bringing osteoblasts and osteoclasts. Endochondral chondro-
cytesundergosequencesofcelldivision,matrixsecretion,cell
hypertrophy, apoptosis, and matrix calcification/mineralisa-
tion. In this study, two critical steps of endochondral bone
formation, the deposition of collagen X-rich matrix and blood
vessel attraction/invasion, were investigated by immunohis-
tochemistry. Fourteen multiple osteochondromas and six
secondary peripheral chondrosarcomas occurring in patients
withmultipleosteochondromaswerestudied and comparedto
epiphyseal growth plate samples. Mutation analysis showed
all studied patients (expect one) to harbour a germ-line
mutations in either EXT1 or EXT2. Here, we described that
homozygous mutations in EXT1/EXT2,w h i c ha r ec a u s a t i v e
for osteochondroma formation, are likely to affect terminal
chondrocyte differentiation and vascularisation in the osteo-
cartilaginous interface. Contrastingly, terminal chondrocyte
differentiation and vascularisation seem to be unaffected in
secondary peripheral chondrosarcoma. In addition, osteo-
chondromas with high vascular density displayed a higher
proliferation rate. A similar apoptotic rate was observed in
osteochondromas and secondary peripheral chondrosarco-
mas. Recently, it has been shown that cells with functional
EXT1 and EXT2 are outnumbering EXT1/EXT2 mutated cells
in secondary peripheral chondrosarcomas. This might ex-
plain the increased type X collagen production and blood





Elongation of long bones is a complex process that requires a
cartilage template, known as the epiphyseal growth plate, and
a strict coordination and synchronisation of cell–cell and cell–
matrix signalling events [1]. The key events in this process
can be divided into two major sequential morphogenesis
phases. The first phase is characterised by the proliferation of
the growth plate chondrocytes, which maintains the pool of
cells needed for bone lengthening. The second phase is a
multistep process characterised by the hypertrophy of
proliferating chondrocytes and bone formation. Hypertrophic
chondrocytes increase their volume and secrete a specialised
extracellular matrix rich in type X collagen [2]. The ossifying
collagen X-rich matrix attracts blood vessels and bone
precursor cells, allowing bone development [3].
Theprocessofendochondralossificationisalsoobservedin
cartilaginoustumours[4]. An active endochondral ossification
takes place deep to the cartilage cap of osteochondroma and
secondary peripheral chondrosarcoma [5].
Osteochondromas are the most common benign bone
tumours at childhood and adolescence [6]. They can occur
either as a sporadic lesion or multiple tumours in hereditary
multiple osteochondromas syndrome (previously known as
hereditary multiple exostoses) [7]. Osteochondromas are
caused by mutations in either EXT1 or EXT2 genes [7].
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projections from the metaphyses of endochondral bones
adjacent to the growth plate [5]. In less than 1% of patients
with sporadic osteochondromas and 1–3% of patients with
multiple osteochondromas at the age of 30–60 years, an
osteochondroma may eventually transform into a secondary
peripheral chondrosarcoma [8].
Whereas osteochondromas have been linked to homozy-
gous mutations in EXT1 or EXT2 genes, cells with functional
EXT1 and EXT2 have been shown to be the predominant
subclone in secondary peripheral chondrosarcomas [9].
Mutations in EXT1 have been demonstrated to impair
angiogenesis in mice [10] and to affect endochondral bone
formation by reducing type X collagen deposition [11].
Endochondral bone formation has been shown to be
affected in the homozygous dak/ext2 zebrafish mutant [12].
EXT1 and EXT2 genes encode enzymes that catalyse the
biosynthesis of heparan sulphate. Heparan sulphate is a key
component of the extracellular matrix acting as co-receptors
for signalling molecules, including vascular endothelial
growth factors (VEGF), fibroblast growth factors (FGF),
and others [13, 14]. The impact of mutations in EXT1 or
EXT2 genes with regards to production of a collagen X-rich
matrix and attraction of blood vessels in osteochondromas
and secondary peripheral chondrosarcomas has not been
investigated so far.
Here, we describe that terminal chondrocyte differenti-
ation and vascularisation are affected in osteochondromas.
Contrastingly, these two critical steps of endochondral bone




Paraffin-embedded tissues from 14 osteochondromas and 6
low-grade secondary peripheral chondrosarcomas from
patients with multiple osteochondromas, collected between
1991 and 2008, were retrieved from the files of the Leiden
University Medical Centre (Table 1). One patient had two
tumours from distinct location included in this study. For
comparison, paraffin-embedded epiphyseal growth plates
(n=3) were obtained from orthopaedic resections for
pathological conditions not related to osteochondroma or
chondrosarcoma. Clinical information and the thickness of
the cartilage cap were obtained from pathology/radiology
reports. All samples were handled in a coded fashion, and
all procedures were performed according to the ethical
guidelines in “Code for Proper Secondary Use of Human
Tissue in the Netherlands” (Dutch Federation of Medical
Scientific Societies).
Immunohistochemistry
Deparaffinised sections were treated with testicular hyaluron-
idase(2mg/mlin0.1-MTrissaline,pH5.0;Sigma-Aldrich,St
Louis, MO, USA, 60 min at 37°C) and proteinase K (5 μl/ml
in 0.1-M Tris-buffered saline, pH 5.0; DakoCytomation,
Carpinteria, CA, USA) followed by overnight incubation at
4°C with monoclonal antibody to collagen X (clone X53,
1:100, Quartett, Berlin, Germany), as previously described [4,
15]. Monoclonal antibody to CD31 (clone JC70A, 1:10,000,
DakoCytomation, Glostrup, Denmark), cleaved caspase-3
(clone 5A1E, 1:100, Cell Signaling Technology, Danvas,
MA, USA), and Ki-67 (clone MIB-1, 1:100, Dako, Glostrup,
Germany) were used as earlier described [16–18]. The
thickness of collagen X-rich matrix was evaluated jointly
by two observers (C.E.A. and S.R.). The thickest collagen X
stained area was identified in each section and measured by
an eye-piece graticule, as described in Fig. 1a. The apoptotic
rate was defined as the number of apoptotic cells (positive
for caspase-3) out of the total number of nucleated cells. The
proliferation rate was determined by counting the numbers of
Ki-67-positive cells.
Estimating vascular density by Chalkley counting
The Chalkley counting method has been previously
described in detail [19]. Briefly, the three most vascular
areas (hot spots) of each section stained with CD31 were
selected and analysed (Fig. 1b). Each vascular hotspot was
viewed at×200 magnification, and a 25-point Chalkley
graticule was applied and oriented to permit the maximum
number of points to hit in or within the CD31 stained blood
vessels [19, 20]. The Chalkley count for each section was
taken as the mean value of the three counts and performed
by two observers independently (C.E.A. and J.V.M.G.B.).
Mutation analysis
Eleven patients were screened by direct sequencing for
DNA mutations in the coding sequence of EXT1 or EXT2
genes [21]. After informed consent, DNAwas isolated from
resected tumours. If no alterations were found, a multiplex
ligation-dependent probe amplification assay designed for
EXT1 and EXT2 genes was performed to identify possible
large deletions, as previously described [22]. Mutation
analysis from six patients has been previously reported [15,
23, 24] (Table 1).
Statistical analysis
Results are expressed as the means with a measure of
variability (standard deviation, S.D.). Statistical signifi-
cance was calculated by one-way analysis of variance with
96 Virchows Arch (2012) 460:95–102Bonferroni's multiple comparison tests. Spearman's rank
correlation coefficient was calculated to verify statistical
dependence between two variables. Both tests were per-
formed using the SPSS 16.0 software package (IBM, Somers,
NY, USA). P values <0.05 were considered significant.
Results
Collagen X-rich matrix in peripheral cartilaginous tumours
The epiphyseal growth plate is organised in columns of
stacked chondrocytes (Fig. 2a). The interface between
cartilaginous and osseous parts in the growth plate (osteocar-
tilaginous interface) was well defined and formed by
hypertrophic chondrocytes immersed in a strong stained
collagen X-rich matrix (Fig. 2d). In the growth plate, the
collagen X-rich matrix was restricted to the hypertrophic
zone and had, on average, 0.8 (± 0.47) mm thickness.
Osteochondromas showed less structured tissue organi-
sation. The osteocartilaginous interface was also less well
defined (Fig. 2b). The collagen X-rich matrix was restricted
to the hypertrophic zone and had, on average, 1.5 (± 1.48)
mm thickness. Additionally, in osteochondroma, not all
chondrocytes with a hypertrophic morphology expressed
type X collagen (Fig. 2e), and when type X collagen was
present, the staining was mainly seen around the chondro-
cytes and not across the matrix (Fig. 2e). In osteochon-
dromas, no correlation was found between the age of the
patient and the thickness of the collagen X-rich matrix
(Spearman's coefficient =0.25).
Secondary peripheral chondrosarcomas showed no
structured tissue organisation (Fig. 2c)a n dh a da n
average cap thickness of 10 mm. Secondary peripheral
Table 1 Clinical information of patients with osteochondroma and secondary peripheral chondrosarcoma





L-741 GP 2 M Femur ––
L-996 GP 8 M Femur ––
L-1142 GP 12 F Tibia ––
L-1234 GP 8 F Femur ––




L-317 OC 31 M Tibia None in EXT1 or EXT2
b 4
L-332 OC 25 M Femur None in EXT1 or EXT2
b 5.5




L-524 OC 26 M Tibia EXT1 codon 164 GAC > CAC (Asp > His),
exon 1: c.1212 G > C, p. D164H
b
4.5
L-722 OC 15 F Radius EXT2 IVS7+1 G > A
b 1.5
L-726 OC 6 M Rib EXT2 IVS7+1 G > A 6
L-841 OC 14 F Femur EXT2 deletion exon 6+7 (del)
b 8
L-1094 OC 6 M Femur EXT2 del exon 6+7 3
L-1143 OC 39 M Femur NA 2
L-2029 OC 23 F Femur EXT2 exon 7: IVS7+1 G > A 3.5
L-2069 OC 11 M Tibia EXT1 exon 1 c.538_539delAG, p.Ser180fsX7
b 5.5
L-2160 OC 48 F Scapula EXT1 exon1 c.538_539delAG, p.Ser180fsX17 6
L-2350 OC 53 F Femur EXT2 exon 7: IVS7+1 G>A 1
L-951 PCH 24 M Fibula NA 8
L-2117 PCH 37 M Humerus EXT1 exon 2: c.1056+1 G>A 12
L-114 PCH 39 M Femur EXT2 exon 5: 764 T>C, L255P (uv)
b 12
L-578 PCH 22 F Femur EXT2 deletion exon 6+7 (del) 11
L-2254 PCH 33 F Pelvis EXT2 exon 6 c.980delG, p.Gly327AlafsX5 8
L-2372 PCH 54 M Rib NA 13
GP epiphyseal growth plate, OC osteochondroma, PCH low grade secondary peripheral chondrosarcoma, NA not analysed
aMutation nomenclature was according to the Nomenclature Working Group [30]; ns non-sense, del deletion, uv unclassified variant, fs frame
shift, pm polymorphism
bResults of mutation previously reported [15, 23, 24]
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stained collagen X-rich matrix (Fig. 2f)w i t ha na v e r a g e
6.5 (± 3.66) mm thickness. Type X collagen expression in
secondary peripheral chondrosarcomas was not restricted to
the osteocartilaginousinterface butwasalsodetectedthrough-
out the extracellular tumour matrix and close to the
perichondrium (data not shown). In secondary peripheral
chondrosarcomas, no correlation was found between the age
of the patient and the thickness of the collagen X-rich matrix
(Spearman's coefficient =0.01).
In osteochondromas and secondary peripheral chondro-
sarcomas, the thickness of the collagen X-rich matrix
correlated with the thickness of the cartilage cap (Spearman's
coefficient =0.63) (Fig. 2g).
Similar apoptotic rates were observed in osteochondromas
and secondary peripheral chondrosarcomas and had values of
35 (± 0.16) % vs. 36 (± 0.15) %, respectively (P=0.847).
Vascular density in the ossification area
Invasion of blood vessels is a critical step towards
ossification of the collagen X-rich matrix. Strong CD31
staining was observed along the cell membrane of
endothelial cells in the epiphyseal growth plate, osteo-
chondroma, and secondary peripheral chondrosarcoma.
The median CD31 vascular density in the growth plate
osteocartilaginous interface was significantly higher than
in osteochondroma, with a value of 10.8 (± 0.83) vs. 6.1
(± 1.79), respectively (P=0.007) (Fig. 3a, b, d). Interest-
ingly, no differences in vascularisation of the osteocarti-
laginous interface were observed between the growth plate
and secondary peripheral chondrosarcoma; a value of 10.8
(± 0.83) vs. 10 (± 0.70) was, respectively, found (P=0.464)
(Fig. 3a, c, d). Moreover, an irregular distribution of blood
vessels was identified in the osteocartilaginous interface of
osteochondromas and peripheral chondrosarcomas, but not
in the epiphyseal growth plates.
In osteochondromas and secondary peripheral chondro-
sarcomas, no association between the age of the patient and
vascular density was found (Spearman's rho correlation
coefficient =0.39 and 0.27, respectively).
In osteochondromas, the proliferation rate ranged from
0–24% in 9 cases to 25–49% in 5 cases. The cases with a
higher proliferation rate (25–49%) showed a higher
Fig. 1 Collagen X-rich matrix
and vascular density by
Chalkley counting. Collagen
X-rich matrix produced by
hypertrophic chondrocytes was
measured from the beginning to
the end of the hypertrophic zone
(a). Chalkley count reflects the
number of grid points that hit
CD31 stained vessels (red
circles)( b). It is more of an
estimate of the relative area than
a true vessel count (a scale bar
10 μm; b scale bars 5 μm)
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proliferation rate (0–24%); a value of 8 (± 0.83) vs. 5.2
(± 1.58) was, respectively, found (P=0.008).
Mutation analysis
Fifteen of 16 patients with multiple osteochondromas
demonstrated a mutation in EXT1 or EXT2 (Table 1). One
patient, from whom two distinct tumours were studied
(L-317 and L-332), displayed no mutations inEXT1 or EXT2.
Additionally, no correlation was found between mutation
type and (a) either tumour type (P=0.564) (b) or the
thickness of the collagen X-rich matrix (P=0.564) (c) or
vascular density (P=0.556).
Discussion
In this study, two crucial steps of endochondral ossifica-
tion, formation of a collagen X-rich matrix and invasion/
attraction of blood vessels, were assessed and compared
in the epiphyseal growth plate and peripheral cartilagi-
nous tumours (osteochondroma and secondary peripheral
chondrosarcoma). The protein expression level of type X
collagen in human osteochondroma was shown to be
similar to the one found in human epiphyseal growth
plate [4]. Interestingly, in the EXT1 heterozygous mutant
mice, in situ hybridisation studies have demonstrated that
the mRNA expression of type X collagen is reduced in the
growth plate as compared to wild-type mice [11, 25]. In
Fig. 2 Collagen X-rich matrix. The epiphyseal growth plate is
organised in columns of stacked chondrocytes (a). Osteochondromas
show less structured organisation (b), and secondary peripheral
chondrosarcomas (c) display no clear organisation. Hypertrophic
chondrocytes secrete a collagen X-rich matrix, which, ultimately, is
replaced by bone (d). In osteochondromas, chondrocytes with a
hypertrophic morphology are not always secreting collagen X (e). In
secondary peripheral chondrosarcoma, a thick layer of collagen X-rich
matrix is observed (f). In osteochondromas and secondary peripheral
chondrosarcomas, the thickness of the cartilage cap correlates with the
thickness of collagen X-rich matrix (g)( scale bars 10 μm)
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be affected in the homozygous dak/ext2 zebrafish mutant
[12]. The reduced type X collagen expression in the EXT1
mutant mice and the delay in endochondral ossification in
the homozygous dak/ext2 zebrafish mutant suggest that
EXT1 and EXT2 genes play a role in terminal chondrocyte
differentiation and the replacement of hypertrophic chon-
drocytes by bone.
Here, we describe that not all of the osteochondroma
cells undergo terminal differentiation. These cells, although
displaying a hypertrophic phenotype, do not express type X
collagen (Fig. 2e). This may suggest that mutations in
EXT1 or EXT2 genes may affect terminal chondrocyte
differentiation in humans. Interestingly, progression of
osteochondroma towards secondary peripheral chondrosar-
coma showed an increased production of type X collagen.
Therefore, the secondary peripheral chondrosarcoma cells
expressing abundant type X collagen indicated that they
have undergone terminal chondrocyte differentiation.
Osteochondromas and secondary peripheral chondrosar-
coma had a similar apoptotic rate. This indicates that,
although secondary peripheral chondrosarcoma cells under-
go terminal differentiation, the differentiation process does
not induce apoptosis. Hence, low cell death seems to
contribute to the relatively rapid growth of peripheral
chondrosarcoma.
Several pro-angiogenic growth factors, such as FGF-2
and VEGFs, bind to heparan sulphate proteoglycans [26].
Heparan sulphate proteoglycans have been shown to
regulate the distribution of these signalling molecules
throughout the extracellular matrix and their receptor
binding affinity [27]. Syndecan-2 is a cell surface heparan
sulphate proteoglycan [26]. Syndecan-2 has been demon-
strated to bind to VEGF, thereby regulating the distribution
of VEGF nearby its receptor [28]. Interestingly, in
osteochondromas, syndecan-2 is no longer located in the
plasma membrane, but is shown to be accumulated in the
Golgi apparatus [24]. The abnormal intracellular location
of syndecan-2 may affect the distribution of VEGF,
explaining the low efficiency of the osteochondroma cells
in attracting blood vessels. Osteochondromas with high
vascular density in the osteocartilaginous interface dis-
played a higher proliferation rate. This might suggest that
proliferation of tumour cells is associated with increased
vascularisation in the osteocartilaginous interface. Inter-
estingly, secondary peripheral chondrosarcomas showed
Fig. 3 Vascular density in the
ossification zone.
The epiphyseal growth plate
(a, d) and secondary peripheral
chondrosarcoma (c, d) show
similar vascular density.
Osteochondroma displays low
vascular density (b, d)( asterisk
indicates P<0.05; scale bars
5 μm)
100 Virchows Arch (2012) 460:95–102similar efficiency in attracting blood vessels as the epiphyseal
growth plate.
We have recently shown that cells with functional EXT1
and EXT2 genes are the predominant subclone in secondary
peripheral chondrosarcomas [9]. Therefore, the increased
type X collagen deposition and blood vessel attraction in
the osteocartilaginous interface of secondary peripheral
chondrosarcoma are possibly associated with cells with
functional EXT1 and EXT2 genes. In addition, collagen X-
rich matrix formation and vascularisation might be useful
prognostic markers of neoplastic transformation of an
osteochondroma, but further validation is required before
they can be proposed as a routine and as a reliable
diagnostic tool.
In conclusion, we show that terminal chondrocyte
differentiation and vascularisation are affected in osteo-
chondromas, suggesting that EXT1 and EXT2 genes are
critical for endochondral bone formation. Terminal chon-
drocyte differentiation and vascularisation seem to be
unaffected in secondary peripheral chondrosarcomas, which
might be associated with the presence of cells with
functional EXT1 and EXT2 genes.
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